Literature DB >> 22322940

Serum ferritin is a cost-effective laboratory marker for hemophagocytic lymphohistiocytosis in the developing world.

Juli Renate Switala1, Marc Hendricks, Alan Davidson.   

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a rare disease in children and presents many diagnostic difficulties. Without prompt intervention, the disease typically runs a rapidly fatal course. Diagnostic criteria were proposed by the Histiocyte Society in 1991 and have since been modified. Included in these criteria is a ferritin level >500 mcg/L. Although not diagnostic, a high ferritin level is highly suggestive of HLH. Serum ferritin assays are more accessible and cost-effective compared with other biochemical markers, particularly in resource-limited settings. Fifteen patients with HLH were treated at Red Cross War Memorial Children's Hospital between 1991 and 2010. Hyperferritinemia was a consistently reliable finding (93%) compared with either serum fibrinogen or triglycerides, which were elevated in only half of the patients. It is our contention that analysis of a complete blood count and serum ferritin (in addition to clinical criteria and tissue examination of marrow and/or cerebrospinal fluid) is probably the single most cost-effective and clinically helpful means to make the diagnosis of HLH when laboratory access is limited.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22322940     DOI: 10.1097/MPH.0b013e31824227b9

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  6 in total

1.  Evaluating the optimal serum ferritin level to identify hemophagocytic lymphohistiocytosis in the critical care setting.

Authors:  Hayder Saeed; Ryan R Woods; Joshua Lester; Roger Herzig; Zartash Gul; Gregory Monohan
Journal:  Int J Hematol       Date:  2015-05-22       Impact factor: 2.490

2.  [Association between HLA-A and HLA-DRB1 allele polymorphisms and susceptibility to tuberculosis in southern Chinese population].

Authors:  Ruiming Yan; Xiaojing Chen; Wei Wang; Li Liang; Chenfei Zhou; Wenfei Wei; Hongyan Yi; Xiangguang Wu; Guobing Liu; Mei Zhong; Yanhong Yu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-01-30

3.  Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

Authors:  David T Teachey; Susan R Rheingold; Shannon L Maude; Gerhard Zugmaier; David M Barrett; Alix E Seif; Kim E Nichols; Erica K Suppa; Michael Kalos; Robert A Berg; Julie C Fitzgerald; Richard Aplenc; Lia Gore; Stephan A Grupp
Journal:  Blood       Date:  2013-05-15       Impact factor: 22.113

4.  Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

Authors:  David T Teachey; Simon F Lacey; Pamela A Shaw; J Joseph Melenhorst; Shannon L Maude; Noelle Frey; Edward Pequignot; Vanessa E Gonzalez; Fang Chen; Jeffrey Finklestein; David M Barrett; Scott L Weiss; Julie C Fitzgerald; Robert A Berg; Richard Aplenc; Colleen Callahan; Susan R Rheingold; Zhaohui Zheng; Stefan Rose-John; Jason C White; Farzana Nazimuddin; Gerald Wertheim; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  Cancer Discov       Date:  2016-04-13       Impact factor: 39.397

5.  Clinical characteristics and prognostic factors of adult hemophagocytic syndrome patients: a retrospective study of increasing awareness of a disease from a single-center in China.

Authors:  Fei Li; Yijun Yang; Fengyan Jin; Casey Dehoedt; Jia Rao; Yulan Zhou; Pu Li; Ganping Yang; Min Wang; Rongyan Zhang; Ye Yang
Journal:  Orphanet J Rare Dis       Date:  2015-02-15       Impact factor: 4.123

6.  Systemic autoimmune abnormalities complicated by cytomegalovirus-induced hemophagocytic lymphohistiocytosis: A case report.

Authors:  Shu-Xian Miao; Zhi-Qi Wu; Hua-Guo Xu
Journal:  World J Clin Cases       Date:  2020-10-26       Impact factor: 1.337

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.